WO2021245432A3 - New pharmaceutical compositions for treatment of covid-19 patients, sepsis and hypoxemia - Google Patents

New pharmaceutical compositions for treatment of covid-19 patients, sepsis and hypoxemia Download PDF

Info

Publication number
WO2021245432A3
WO2021245432A3 PCT/GR2021/000013 GR2021000013W WO2021245432A3 WO 2021245432 A3 WO2021245432 A3 WO 2021245432A3 GR 2021000013 W GR2021000013 W GR 2021000013W WO 2021245432 A3 WO2021245432 A3 WO 2021245432A3
Authority
WO
WIPO (PCT)
Prior art keywords
patients
hypoxemia
covid
treatment
blue
Prior art date
Application number
PCT/GR2021/000013
Other languages
French (fr)
Other versions
WO2021245432A2 (en
Inventor
Daryoush Hamidi ALAMDARI
Aida Hamidi ALMADARI
Ahmed Bagheri MOGHADDAM
Mohammadamin DAMSAZ
Original Assignee
Biohellenika S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohellenika S.A. filed Critical Biohellenika S.A.
Publication of WO2021245432A2 publication Critical patent/WO2021245432A2/en
Publication of WO2021245432A3 publication Critical patent/WO2021245432A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Hypoxemia is one of the main complications of COVID-19 patients diabetic patients. Reduced methylene blue (lecumethylene blue) can be applied as pharmacological intervention for the treatment of hypoxemia. Lecumethylene blue as active compound of this composition along with other mentioned antioxidants, in addition to correction of hypoxemia can decrease the viral load, inflammation, oxidative stress in patients especially COVID-19 patients. The addition of LMB to the standard treatment protocols for severe COVID-19 patients was associated with statistically significant clinical benefits resulted in decreasing hospital stay and 28-day mortality. Lecumethylene blue can also applied for treatment of other diseases such as diabetic patients and etcetera.
PCT/GR2021/000013 2020-06-01 2021-02-26 New pharmaceutical compositions for treatment of covid-19 patients, sepsis and hypoxemia WO2021245432A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IRIR-139950140003002083 2020-06-01
IR13993002083 2020-06-01

Publications (2)

Publication Number Publication Date
WO2021245432A2 WO2021245432A2 (en) 2021-12-09
WO2021245432A3 true WO2021245432A3 (en) 2022-03-24

Family

ID=78831724

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GR2021/000013 WO2021245432A2 (en) 2020-06-01 2021-02-26 New pharmaceutical compositions for treatment of covid-19 patients, sepsis and hypoxemia

Country Status (1)

Country Link
WO (1) WO2021245432A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202204185D0 (en) * 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3045179A1 (en) * 2013-08-20 2016-07-20 Fuchao Li Local anesthesia pain-relieving time-delay agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3045179A1 (en) * 2013-08-20 2016-07-20 Fuchao Li Local anesthesia pain-relieving time-delay agent

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"The Clinical Trial of Application of methylene Blue Vial for Treatment of Covid-19 Patients", 30 April 2020 (2020-04-30), XP002804611, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT04370288> *
ALAMDARI DARYOUSH HAMIDI ET AL: "Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 885, 20 August 2020 (2020-08-20), XP086272954, ISSN: 0014-2999, [retrieved on 20200820], DOI: 10.1016/J.EJPHAR.2020.173494 *
DARYOUSH HAMIDI ALAMDARI ET AL: "The Application of a Reduced Dye Used in Orthopedics as a Novel Treatment against Coronavirus (COVID-19): A Suggested Therapeutic Protocol", THE ARCHIVES OF BONE AND JOINT SURGERY, vol. 8, no. 1, 12 April 2020 (2020-04-12) - 12 April 2020 (2020-04-12), pages 291-294, XP055762802 *
DEEPAK GOLWALKAR: "Treatment for COVID-19 using Methylene Blue", 8 February 2020 (2020-02-08), pages 1 - 4, XP055737722, Retrieved from the Internet <URL:https://methylene-blue.conzapp.com/treatment-for-covid-19-using-methylene-blue> [retrieved on 20201007] *
MIYAMOTO AKIKO ET AL: "Effect of chronic methylene blue administration on hypoxemia in rats with common bile duct ligation : Methylene blue in rats with hypoxemia", HEPATOLOGY RESEARCH, vol. 40, no. 6, 14 April 2010 (2010-04-14), NL, pages 622 - 632, XP055820697, ISSN: 1386-6346, DOI: 10.1111/j.1872-034X.2010.00640.x *

Also Published As

Publication number Publication date
WO2021245432A2 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
US10500235B2 (en) Wound healing compositions comprising buckwheat honey and methylglyoxal and methods of use
US6258385B1 (en) Tetrasilver tetroxide treatment for skin conditions
MY137060A (en) Topical pharmaceutical compositions comprising proanthocyanidins, glycyrrhetinic acid and telmesteine for the treatment of dermatitis
WO2021245432A3 (en) New pharmaceutical compositions for treatment of covid-19 patients, sepsis and hypoxemia
UY29410A1 (en) PHARMACEUTICAL COMPOSITIONS BASED ON METHODAMIDES OF ACID 4- (4 - / - 3 (-4-CHLORO-3-TRIFLUOROMETIFENIL) UREIDO) FENOXI) PIRIDIN-2-CARBOXYLIC, PREPARATION PROCEDURE AND APPLICATIONS.
Messier et al. Inhibition of Candida albicans biofilm formation and yeast-hyphal transition by 4-hydroxycordoin
Altan et al. The effect of Hypericum Perforatum on wound healing of oral mucosa in diabetic rats
KR101861347B1 (en) Compositions for the treatment of peripheral ulcers of various origins
HUP0402075A2 (en) Compositions for treatment of common cold
MX2021001276A (en) Bismuth-thiol compositions and methods for treating wounds.
Banaeian-Borujeni et al. Comparison of the effect of honey and miconazole against Candida albicans in vitro
US6352711B1 (en) Lesion and ulcer medication
EP4400098A3 (en) Co-amorphous forms of beta-lactoglobulin and a drug substance
DE60016394D1 (en) SALTS OF ASIC ACID AND MADECASSIC ACID SUITABLE FOR THE PREPARATION OF PHARMACEUTICAL AND COSMETIC COMPOSITIONS
CA3153877C (en) Curcuminoid composition and its therapeutic potential in managing lung fibrosis
EP2556834B1 (en) Tetrathiomolybdate for use in the treatment of ischemia-reperfusion injury of the heart
EP2482667B1 (en) Leaven-based mixture
SG11201903077SA (en) Composition comprising organic selenium compound
KR101590042B1 (en) Composition for protecting and treating vaginosis disease comprising the purified fraction isolated from bee venom
Anselm et al. Brugada phenocopy in a patient with surgically repaired pentalogy of Fallot
Kochar et al. Role of nano-collagen particles dressing in the management of chronic ulcer: a prospective non-randomized trial on 100 cases
CA2384192C (en) Pharmaceutical composition, comprising eucalyptus oil and orange oil
CN110693819B (en) Pharmaceutical composition for preventing and treating acarid dermatitis and preparation method thereof
Turrentine et al. Acute generalized exanthematous pustulosis (AGEP) caused by telavancin
Dutto et al. Local intense and systemic reactions to Aedes albopictus (Diptera, Culicidae) bites: a clinical case report

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21725583

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21725583

Country of ref document: EP

Kind code of ref document: A2